Targeted partial reprogramming as a novel therapeutic strategy for age-related decline.

Max Rose, Eli Y Adashi

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. Electronic address: [email protected] of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. Electronic address: [email protected]. · pubmed

Paper

Abstract

Cellular reprogramming has emerged as a promising strategy for the amelioration of age-associated cellular phenotypes. In-vivo reprogramming approaches, however, have been limited by a lack of specificity and oncogenic risk. Recent breakthroughs have addressed these limitations, constituting a significant progression toward the development of safe and effective therapeutics for age-related pathologies.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that targeted partial reprogramming can ameliorate age-related cellular phenotypes. This research addresses the root causes of aging by exploring cellular reprogramming as a therapeutic strategy, which is directly relevant to longevity and age-related decline.

Author of this paper? Send a correction.